Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Red Dragon who wrote (871)	1/21/1998 9:51:00 AM
From: MCorbley	Read Replies (1) \| Respond to of 1115

The data do not support Scenario B. I agree that things are pretty screwed up at Lidak right now. However, if one were to forget about the company for a minute, forget that there is money involved and just look at the published data on Lidakol from a scientic perspective, one would conclude that the evidence is on the side of Lidakol being an effective treatment for Herpes. Your suggestion that Lidakol is statistically comparable but actually inferior to acyclovir is formally possible. But the data up to this point strongly indicate that the opposite is true. I am not trying to make the data sound good because I own the stock; rather I own the stock because the data look good. I and others have posted numerous summaries of the previously published data earlier on this thread. There has also been a good discussion of statistics on the Yahoo thread between #150-300. One post which is particularly germane to your comment about lies and statistics is: messages.yahoo.com@m2.yahoo.com. Since the clinical trial is a fait accompli, this speculation about what the statistics will turn out to be is perhaps superfluous and Lidakol may already be a goner. But the earlier data were really very good.